Delta Diagnostics trading Elucigene Diagnostics

Elucigene Diagnostics, legally known as Delta Diagnostics (UK) Ltd, is a Manchester-based company that designs, manufactures, and develops molecular diagnostic products. The company's portfolio is centered on reproductive health and oncology, offering in-vitro diagnostic assays for conditions like cystic fibrosis, aneuploidy, and other genetic disorders.

The company's core technology utilizes Quantitative Fluorescence-Polymerase Chain Reaction (QF-PCR) to enable rapid and accurate genetic analysis. Its key products include kits for prenatal screening of chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, as well as solutions for analyzing pregnancy loss. These products are designed for use by clinical laboratories to simplify and expedite the testing process.

Elucigene was established in 2013, originating from a management buyout of a division from the molecular diagnostics group Gen-Probe, which was part of Hologic. The buyout was led by a team including Scott Higgins and was backed by Percipient Capital. In April 2019, Elucigene was acquired by Yourgene Health, an international molecular diagnostics group, for approximately £9.2 million. This acquisition was intended to create an enlarged group with increased scale and to accelerate Yourgene's path to profitability by expanding its product portfolio and international reach.

Keywords: molecular diagnostics, reproductive health, in-vitro diagnostics, genetic testing, QF-PCR, aneuploidy screening, cystic fibrosis testing, prenatal screening, oncology assays, chromosome analysis, genetic disorders, Down syndrome testing, personalized medicine, diagnostic kits, CE-IVD, cytogenetics, polymerase chain reaction, genomics, medical diagnostics